Explore cutting-edge studies in tumor biology, molecular pathways, and clinical breakthroughs
Discover how SAR650984 (isatuximab) disrupts the CD38-CD31 adhesion axis in multiple myeloma, unmoors cancer cells from bone marrow, and triggers multiple lethal pathways.